Pharmaceuticals and healthcare markets can seem as intricate and opaque as they are vital to consumers wellbeing, which makes them crucial sectors for antitrust scrutiny. Our analysis of drug pricing data helps to identify the markets in which pharmaceutical manufacturers collude to raise prices, and our expert testimony on the economics of drug industry helps plaintiffs recover damages. In healthcare markets, Fideres has led pioneering work on market definition and overcharge analysis in the increasingly-concentrated and expensive regional hospital markets of the United States. Sample cases include:

  • Clobetasol price-fixing antitrust class action, US – pre-filing economic investigation to identify evidence of collusion and other plus factors, 2:16-md-02724

  • Doxycycline price-fixing antitrust class action, US – pre-filing economic investigation to identify evidence of collusion and other plus factors, 2:16-cv-01388-CMR

  • Econazole price-fixing antitrust class action, US – pre-filing economic investigation to identify evidence of collusion and other plus factors, 2:16-md-02724

  • Digoxin price-fixing antitrust class action, US – pre-filing economic investigation to identify evidence of collusion and other plus factors, 2:16-md-02724

  • Clomipramine price-fixing antitrust class action, US – pre-filing economic investigation to identify evidence of collusion and other plus factors, 2:16-md-02724

  • Ursodiol Generic Drug 2:16-md-02724

  • Novo Nordisk (Insulin) monopolization class action, US – pre-filing economic analysis and damages modelling, 3:17-cv-00209-BRM-LHG

  • EpiPen market monopolization consumers antitrust class action, US – pre-filing economic analysis and damages modelling, 0:17-cv-01884

  • Hospital monopolization antitrust class action, US – expert consulting appointment for class certification report, 16-CVS-16404